Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target
1. Cognition Therapeutics reports 75% enrollment in Phase 2 START Study. 2. START Study involves 540 patients with mild cognitive impairment and early Alzheimer's. 3. Funding comes from an $81 million grant from the National Institute of Aging. 4. Zervimesine shows potential in slowing cognitive decline based on previous studies. 5. The drug targets protein buildup in neurodegenerative diseases such as Alzheimer’s.